APO Research
Talk to an analyst

APO RESEARCH · REPORT

Adalimumab

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Adalimumab Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025181 pages

Choose your research edition.

Industry ResearchAdalimumab Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Adalimumab Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Adalimumab Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Adalimumab Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Adalimumab Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Adalimumab market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Adalimumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Adalimumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Adalimumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Adalimumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Adalimumab include Aark Pharmaceuticals, Amgevita, Biogen, Boehringer Ingelheim, Delphis Pharma, AbbVie, Amgen, Mylan and Sandoz, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Adalimumab market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Adalimumab and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Adalimumab sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Adalimumab market size, projected growth trends, production technologies, key applications, and end-use industries.

Adalimumab Segment by Company

Aark Pharmaceuticals

Amgevita

Biogen

Boehringer Ingelheim

Delphis Pharma

AbbVie

Amgen

Mylan

Sandoz

Adalimumab Segment by Type

Adalimumab

Adalimumab Biosimilar

Adalimumab Segment by Application

Adults

Children

Adalimumab Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Adalimumab market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Adalimumab and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Adalimumab.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Adalimumab market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Adalimumab manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Adalimumab in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Adalimumab in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Adalimumab Industry Trends Table 2. Adalimumab Industry Drivers Table 3. Adalimumab Industry Opportunities and Challenges Table 4. Adalimumab Industry Restraints Table 5. Global Adalimumab Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Adalimumab Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Adalimumab Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Adalimumab Sales Market Share by Manufacturers Table 9. Global Adalimumab Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Adalimumab Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Adalimumab Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Adalimumab Manufacturers, Product Type & Application Table 13. Global Adalimumab Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Adalimumab by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Adalimumab Table 17. Major Manufacturers of Adalimumab Biosimilar Table 18. Global Adalimumab Sales by Type 2021 VS 2025 VS 2032 (k units) Table 19. Global Adalimumab Sales by Type (2021-2026) & (k units) Table 20. Global Adalimumab Sales by Type (2027-2032) & (k units) Table 21. Global Adalimumab Sales Market Share by Type (2021-2026) Table 22. Global Adalimumab Sales Market Share by Type (2027-2032) Table 23. Global Adalimumab Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Adalimumab Revenue by Type (2021-2026) & (k units) Table 25. Global Adalimumab Revenue by Type (2027-2032) & (k units) Table 26. Global Adalimumab Revenue Market Share by Type (2021-2026) Table 27. Global Adalimumab Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Adults Table 29. Major Manufacturers of Children Table 30. Global Adalimumab Sales by Application 2021 VS 2025 VS 2032 (k units) Table 31. Global Adalimumab Sales by Application (2021-2026) & (k units) Table 32. Global Adalimumab Sales by Application (2027-2032) & (k units) Table 33. Global Adalimumab Sales Market Share by Application (2021-2026) Table 34. Global Adalimumab Sales Market Share by Application (2027-2032) Table 35. Global Adalimumab Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 36. Global Adalimumab Revenue by Application (2021-2026) & (k units) Table 37. Global Adalimumab Revenue by Application (2027-2032) & (k units) Table 38. Global Adalimumab Revenue Market Share by Application (2021-2026) Table 39. Global Adalimumab Revenue Market Share by Application (2027-2032) Table 40. Global Adalimumab Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 41. Global Adalimumab Sales by Region (2021-2026) & (k units) Table 42. Global Adalimumab Sales Market Share by Region (2021-2026) Table 43. Global Adalimumab Sales Forecasted by Region (2027-2032) & (k units) Table 44. Global Adalimumab Sales Forecasted Market Share by Region (2027-2032) Table 45. North America Adalimumab Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 46. North America Adalimumab Sales by Country (2021-2026) & (k units) Table 47. North America Adalimumab Sales by Country (2027-2032) & (k units) Table 48. Europe Adalimumab Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 49. Europe Adalimumab Sales by Country (2021-2026) & (k units) Table 50. Europe Adalimumab Sales by Country (2027-2032) & (k units) Table 51. Asia Pacific Adalimumab Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 52. Asia Pacific Adalimumab Sales by Country (2021-2026) & (k units) Table 53. Asia Pacific Adalimumab Sales by Country (2027-2032) & (k units) Table 54. South America, Middle East and Africa Adalimumab Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 55. South America, Middle East and Africa Adalimumab Sales by Country (2021-2026) & (k units) Table 56. South America, Middle East and Africa Adalimumab Sales by Country (2027-2032) & (k units) Table 57. Global Adalimumab Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Adalimumab Revenue by Region (2021-2026) & (US$ Million) Table 59. Global Adalimumab Revenue by Region (2027-2032) & (US$ Million) Table 60. Global Adalimumab Revenue Market Share by Region (2021-2026) Table 61. Global Adalimumab Revenue Market Share by Region (2027-2032) Table 62. Aark Pharmaceuticals Company Information Table 63. Aark Pharmaceuticals Business Overview Table 64. Aark Pharmaceuticals Adalimumab Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Aark Pharmaceuticals Adalimumab Product Portfolio Table 66. Aark Pharmaceuticals Recent Development Table 67. Amgevita Company Information Table 68. Amgevita Business Overview Table 69. Amgevita Adalimumab Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Amgevita Adalimumab Product Portfolio Table 71. Amgevita Recent Development Table 72. Biogen Company Information Table 73. Biogen Business Overview Table 74. Biogen Adalimumab Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Biogen Adalimumab Product Portfolio Table 76. Biogen Recent Development Table 77. Boehringer Ingelheim Company Information Table 78. Boehringer Ingelheim Business Overview Table 79. Boehringer Ingelheim Adalimumab Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Boehringer Ingelheim Adalimumab Product Portfolio Table 81. Boehringer Ingelheim Recent Development Table 82. Delphis Pharma Company Information Table 83. Delphis Pharma Business Overview Table 84. Delphis Pharma Adalimumab Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Delphis Pharma Adalimumab Product Portfolio Table 86. Delphis Pharma Recent Development Table 87. AbbVie Company Information Table 88. AbbVie Business Overview Table 89. AbbVie Adalimumab Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. AbbVie Adalimumab Product Portfolio Table 91. AbbVie Recent Development Table 92. Amgen Company Information Table 93. Amgen Business Overview Table 94. Amgen Adalimumab Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Amgen Adalimumab Product Portfolio Table 96. Amgen Recent Development Table 97. Mylan Company Information Table 98. Mylan Business Overview Table 99. Mylan Adalimumab Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Mylan Adalimumab Product Portfolio Table 101. Mylan Recent Development Table 102. Sandoz Company Information Table 103. Sandoz Business Overview Table 104. Sandoz Adalimumab Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Sandoz Adalimumab Product Portfolio Table 106. Sandoz Recent Development Table 107. Key Raw Materials Table 108. Raw Materials Key Suppliers Table 109. Adalimumab Distributors List Table 110. Adalimumab Customers List Table 111. Research Programs/Design for This Report Table 112. Authors List of This Report Table 113. Secondary Sources Table 114. Primary Sources List of Figures Figure 1. Adalimumab Product Image Figure 2. Global Adalimumab Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Adalimumab Market Size (2021-2032) & (US$ Million) Figure 4. Global Adalimumab Sales (2021-2032) & (k units) Figure 5. Global Adalimumab Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Adalimumab Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Adalimumab Image Figure 9. Adalimumab Biosimilar Image Figure 10. Global Adalimumab Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 11. Global Adalimumab Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Adalimumab Sales Market Share by Type (2021-2032) Figure 13. Global Adalimumab Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Adalimumab Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Adalimumab Revenue Market Share by Type (2021-2032) Figure 16. Adults Image Figure 17. Children Image Figure 18. Global Adalimumab Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 19. Global Adalimumab Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global Adalimumab Sales Market Share by Application (2021-2032) Figure 21. Global Adalimumab Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Adalimumab Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Adalimumab Revenue Market Share by Application (2021-2032) Figure 24. North America Adalimumab Sales and Growth Rate (2021-2032) & (k units) Figure 25. North America Adalimumab Sales Market Share by Country (2021-2032) Figure 26. U.S. Adalimumab Sales and Growth Rate (2021-2032) & (k units) Figure 27. Canada Adalimumab Sales and Growth Rate (2021-2032) & (k units) Figure 28. Mexico Adalimumab Sales and Growth Rate (2021-2032) & (k units) Figure 29. Europe Adalimumab Sales and Growth Rate (2021-2032) & (k units) Figure 30. Europe Adalimumab Sales Market Share by Country (2021-2032) Figure 31. Germany Adalimumab Sales and Growth Rate (2021-2032) & (k units) Figure 32. France Adalimumab Sales and Growth Rate (2021-2032) & (k units) Figure 33. U.K. Adalimumab Sales and Growth Rate (2021-2032) & (k units) Figure 34. Italy Adalimumab Sales and Growth Rate (2021-2032) & (k units) Figure 35. Netherlands Adalimumab Sales and Growth Rate (2021-2032) & (k units) Figure 36. Asia Pacific Adalimumab Sales and Growth Rate (2021-2032) & (k units) Figure 37. Asia Pacific Adalimumab Sales Market Share by Country (2021-2032) Figure 38. China Adalimumab Sales and Growth Rate (2021-2032) & (k units) Figure 39. Japan Adalimumab Sales and Growth Rate (2021-2032) & (k units) Figure 40. South Korea Adalimumab Sales and Growth Rate (2021-2032) & (k units) Figure 41. Southeast Asia Adalimumab Sales and Growth Rate (2021-2032) & (k units) Figure 42. India Adalimumab Sales and Growth Rate (2021-2032) & (k units) Figure 43. Australia Adalimumab Sales and Growth Rate (2021-2032) & (k units) Figure 44. South America, Middle East and Africa Adalimumab Sales and Growth Rate (2021-2032) & (k units) Figure 45. South America, Middle East and Africa Adalimumab Sales Market Share by Country (2021-2032) Figure 46. Brazil Adalimumab Sales and Growth Rate (2021-2032) & (k units) Figure 47. South Africa Adalimumab Sales and Growth Rate (2021-2032) & (k units) Figure 48. Saudi Arabia Adalimumab Sales and Growth Rate (2021-2032) & (k units) Figure 49. Turkey Adalimumab Sales and Growth Rate (2021-2032) & (k units) Figure 50. Argentina Adalimumab Sales and Growth Rate (2021-2032) & (k units) Figure 51. UAE Adalimumab Sales and Growth Rate (2021-2032) & (k units) Figure 52. Egypt Adalimumab Sales and Growth Rate (2021-2032) & (k units) Figure 53. Chile Adalimumab Sales and Growth Rate (2021-2032) & (k units) Figure 54. Global Adalimumab Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Global Adalimumab Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 56. North America Adalimumab Revenue (2021-2032) & (US$ Million) Figure 57. North America Adalimumab Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 58. Europe Adalimumab Revenue (2021-2032) & (US$ Million) Figure 59. Europe Adalimumab Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Asia-Pacific Adalimumab Revenue (2021-2032) & (US$ Million) Figure 61. Asia-Pacific Adalimumab Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. South America, Middle East and Africa Adalimumab Revenue (2021-2032) & (US$ Million) Figure 63. South America, Middle East and Africa Adalimumab Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Adalimumab Value Chain Figure 65. Manufacturing Cost Structure Figure 66. Adalimumab Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Adalimumab
  • Adalimumab Biosimilar
Applications
  • Adults
  • Children
Companies covered
  • Aark Pharmaceuticals
  • Amgevita
  • Biogen
  • Boehringer Ingelheim
  • Delphis Pharma
  • AbbVie
  • Amgen
  • Mylan
  • Sandoz

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Adalimumab Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Adalimumab Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Adalimumab Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Adalimumab Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Adalimumab Market Dynamics
  1. 2.1 Adalimumab Industry Trends
  2. 2.2 Adalimumab Industry Drivers
  3. 2.3 Adalimumab Industry Opportunities and Challenges
  4. 2.4 Adalimumab Industry Restraints
3 Adalimumab Market by Manufacturers
  1. 3.1 Global Adalimumab Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Adalimumab Sales by Manufacturers (2021-2026)
  3. 3.3 Global Adalimumab Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Adalimumab Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Adalimumab Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Adalimumab Manufacturers, Product Type & Application
  7. 3.7 Global Adalimumab Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Adalimumab Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Adalimumab Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Adalimumab Tier 1, Tier 2, and Tier 3
4 Adalimumab Market by Type
  1. 4.1 Adalimumab Type Introduction
  2. 4.1.1 Adalimumab
  3. 4.1.2 Adalimumab Biosimilar
  4. 4.2 Global Adalimumab Sales by Type
  5. 4.2.1 Global Adalimumab Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Adalimumab Sales by Type (2021-2032)
  7. 4.2.3 Global Adalimumab Sales Market Share by Type (2021-2032)
  8. 4.3 Global Adalimumab Revenue by Type
  9. 4.3.1 Global Adalimumab Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Adalimumab Revenue by Type (2021-2032)
  11. 4.3.3 Global Adalimumab Revenue Market Share by Type (2021-2032)
5 Adalimumab Market by Application
  1. 5.1 Adalimumab Application Introduction
  2. 5.1.1 Adults
  3. 5.1.2 Children
  4. 5.2 Global Adalimumab Sales by Application
  5. 5.2.1 Global Adalimumab Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Adalimumab Sales by Application (2021-2032)
  7. 5.2.3 Global Adalimumab Sales Market Share by Application (2021-2032)
  8. 5.3 Global Adalimumab Revenue by Application
  9. 5.3.1 Global Adalimumab Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Adalimumab Revenue by Application (2021-2032)
  11. 5.3.3 Global Adalimumab Revenue Market Share by Application (2021-2032)
6 Global Adalimumab Sales by Region
  1. 6.1 Global Adalimumab Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Adalimumab Sales by Region (2021-2032)
  3. 6.2.1 Global Adalimumab Sales by Region (2021-2026)
  4. 6.2.2 Global Adalimumab Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Adalimumab Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Adalimumab Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Adalimumab Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Adalimumab Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Adalimumab Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Adalimumab Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Adalimumab Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Adalimumab Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Adalimumab Revenue by Region
  1. 7.1 Global Adalimumab Revenue by Region
  2. 7.1.1 Global Adalimumab Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Adalimumab Revenue by Region (2021-2026)
  4. 7.1.3 Global Adalimumab Revenue by Region (2027-2032)
  5. 7.1.4 Global Adalimumab Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Adalimumab Revenue (2021-2032)
  8. 7.2.2 North America Adalimumab Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Adalimumab Revenue (2021-2032)
  11. 7.3.2 Europe Adalimumab Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Adalimumab Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Adalimumab Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Adalimumab Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Adalimumab Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Aark Pharmaceuticals
  2. 8.1.1 Aark Pharmaceuticals Company Information
  3. 8.1.2 Aark Pharmaceuticals Business Overview
  4. 8.1.3 Aark Pharmaceuticals Adalimumab Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Aark Pharmaceuticals Adalimumab Product Portfolio
  6. 8.1.5 Aark Pharmaceuticals Recent Developments
  7. 8.2 Amgevita
  8. 8.2.1 Amgevita Company Information
  9. 8.2.2 Amgevita Business Overview
  10. 8.2.3 Amgevita Adalimumab Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Amgevita Adalimumab Product Portfolio
  12. 8.2.5 Amgevita Recent Developments
  13. 8.3 Biogen
  14. 8.3.1 Biogen Company Information
  15. 8.3.2 Biogen Business Overview
  16. 8.3.3 Biogen Adalimumab Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Biogen Adalimumab Product Portfolio
  18. 8.3.5 Biogen Recent Developments
  19. 8.4 Boehringer Ingelheim
  20. 8.4.1 Boehringer Ingelheim Company Information
  21. 8.4.2 Boehringer Ingelheim Business Overview
  22. 8.4.3 Boehringer Ingelheim Adalimumab Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Boehringer Ingelheim Adalimumab Product Portfolio
  24. 8.4.5 Boehringer Ingelheim Recent Developments
  25. 8.5 Delphis Pharma
  26. 8.5.1 Delphis Pharma Company Information
  27. 8.5.2 Delphis Pharma Business Overview
  28. 8.5.3 Delphis Pharma Adalimumab Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Delphis Pharma Adalimumab Product Portfolio
  30. 8.5.5 Delphis Pharma Recent Developments
  31. 8.6 AbbVie
  32. 8.6.1 AbbVie Company Information
  33. 8.6.2 AbbVie Business Overview
  34. 8.6.3 AbbVie Adalimumab Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 AbbVie Adalimumab Product Portfolio
  36. 8.6.5 AbbVie Recent Developments
  37. 8.7 Amgen
  38. 8.7.1 Amgen Company Information
  39. 8.7.2 Amgen Business Overview
  40. 8.7.3 Amgen Adalimumab Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Amgen Adalimumab Product Portfolio
  42. 8.7.5 Amgen Recent Developments
  43. 8.8 Mylan
  44. 8.8.1 Mylan Company Information
  45. 8.8.2 Mylan Business Overview
  46. 8.8.3 Mylan Adalimumab Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Mylan Adalimumab Product Portfolio
  48. 8.8.5 Mylan Recent Developments
  49. 8.9 Sandoz
  50. 8.9.1 Sandoz Company Information
  51. 8.9.2 Sandoz Business Overview
  52. 8.9.3 Sandoz Adalimumab Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Sandoz Adalimumab Product Portfolio
  54. 8.9.5 Sandoz Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Adalimumab Value Chain Analysis
  2. 9.1.1 Adalimumab Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Adalimumab Production Mode & Process
  6. 9.2 Adalimumab Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Adalimumab Distributors
  9. 9.2.3 Adalimumab Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst